BLOG: Bimatoprost implant provides innovative option for glaucoma management
By Merin Abraham, OD
Several novel modes of treatment are now available to eye care providers to treat glaucoma, although topical medications remain the most common modality. A major determinant of the success of topical therapy is the degree to which patients are compliant with eye drops use. Whereas some patients may miss their scheduled dosing due to forgetfulness, patients often make the deliberate choice to discontinue therapy or change their dose of medication. This regularly occurs due to side effects associated with their prescribed medications or other issues such as limited mobility and dexterity. Alternative methods, such as laser trabeculoplasty and MIGS, have gained popularity in hopes of improving patients’ compliance and quality of life.
Durysta is an intracameral, biodegradable bimatoprost implant (10 mcg) approved in March 2020 by the U.S. Food and Drug Administration for use in patients with open-angle glaucoma and ocular hypertension. In the ARTEMIS studies 1 and 2, which led to FDA approval, Durysta was found to reduce interocular pressure (IOP) by approximately 30% from baseline over the 12-week primary efficacy period and also showed a prolonged IOP-lowering effect for >6 months in many patients, despite being designed to last 4-6 months. Durysta is contraindicated in patients with corneal endothelial cell dystrophy, prior corneal transplant, absent or torn posterior capsule, and any previous hypersensitivity to bimatoprost. Additionally, it should be used with caution in patients with narrow angles and a history of intraocular inflammation or macular edema. With its most common adverse reaction being conjunctival hyperemia, Durysta has a promising safety profile and is an innovative option for glaucoma management.
Dr Abraham practices full-scope optometry at Marano Eye Care in New Jersey. She is affiliated with Saint Barnabas Medical Center in Livingston, NJ, and St. Michael’s Medical Center in Newark, NJ.
